We are live on ! Find out more
AICPI

ABG Innovation Capital Partners III Portfolio holdings

AUM $64.5K
1-Year Est. Return 1.01%
This Fund
S&P 500
This Quarter Est. Return
-58.9%
1 Year Est. Return
+1.01%
3 Year Est. Return
+5.56%
5 Year Est. Return
-85.52%
10 Year Est. Return
–
AUM
$29.9M
AUM Growth
-$174M
Cap. Flow
-$161M
Cap. Flow %
-539.11%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
AVIR icon
Atea Pharmaceuticals
AVIR
+$38M

Top Sells

Rank Stock Value
1
LUNG icon
Pulmonx
LUNG
+$36.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVIR icon
1
Atea Pharmaceuticals
AVIR
$380M
$27.2M 91.01%
+1,265,631
New +$38M
GNCA
2
DELISTED
Genocea Biosciences, Inc.
GNCA
$878K 2.94%
375,000
– –
SYBX
3
DELISTED
Synlogic
SYBX
$801K 2.68%
13,727
– –
WHWK
4
Whitehawk Therapeutics
WHWK
$208M
$676K 2.26%
26,667
– –
LUNG icon
5
Pulmonx
LUNG
$79.8M
$199K 0.67%
4,521
-828,812
-99% -$36.1M
ACGN
6
DELISTED
Aceragen Inc
ACGN
$68K 0.23%
3,312
– –
NBRV
7
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$62K 0.21%
1,834
– –

Similar funds

FFVM
Founders Fund VI Management San Francisco, California $45.8K AUM 58.63% 1-Year Est. Return
SNN
Shen Neil Nanpeng $36.3K AUM 179.45% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
MI
Motiv8 Investments Port St. Lucie, Florida $183K AUM 15.06% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return
NA
Newport Asia San Francisco, California $2.21M AUM
IVSFI
IA Venture Strategies Fund II New York $4.08M AUM 174.71% 1-Year Est. Return

ABG Innovation Capital Partners III's Q2 2021 Portfolio in Review

As of Q2 2021, ABG Innovation Capital Partners III held 8 positions worth $29.9M, down 85% from $204M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG Innovation Capital Partners III withdrew a net $161M in Q2 2021, closing 1 position and reducing 1 holding. Its largest reduction was Pulmonx, cutting an estimated $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 20% a quarter earlier.

Against the trend, ABG Innovation Capital Partners III opened a new position in Atea Pharmaceuticals worth $27.2M.

  • ABG Innovation Capital Partners III's largest Q2 2021 buy was Atea Pharmaceuticals: 1,265,631 shares worth $27.2M.
  • ABG Innovation Capital Partners III's biggest Q2 2021 reduction was Pulmonx, cutting an estimated $36.1M.
  • ABG Innovation Capital Partners III's ten largest holdings make up 100% of its $29.9M portfolio in Q2 2021.
  • ABG Innovation Capital Partners III opened 1 new position and closed 1 in Q2 2021.
  • ABG Innovation Capital Partners III's portfolio value fell 85% quarter-over-quarter to $29.9M.

Based on ABG Innovation Capital Partners III's 13F filing for Q2 2021, filed 16 Aug 2021.